BetterMe Rx review

BetterMe Rx names seven pharmacy partners and two clinical networks. That is useful disclosure, but it neither independently verifies credentials nor identifies the pharmacy for a specific prescription. No numeric sermorelin or NAD⁺ price was found on reviewed public pages, and the billing and cancellation language differs across the FAQ, terms and return policy.

BetterMe Rx is a direct-to-consumer telehealth platform stating service in all 50 states, displaying a LegitScript seal, and naming the Telegra MD and Dr Telx networks as its provider network. Its weight-loss line is compounded semaglutide and tirzepatide injections plus a GLP-1 microdosing program. The wider platform also runs ED and a wellness line — sermorelin as a nightly injection or a daily oral tablet, and NAD⁺ as an injection or a nasal spray. Estrogen and progesterone HRT is listed as coming soon.

The FAQ names EpiqScripts, Valiant RX, GoGoMeds, The Pharmacy Hub, Emerald, Striker and Belmar, plus Telegra MD and Dr Telx. It describes online review with live contact where required. Ask which provider and pharmacy handle your product. The sermorelin page makes lab requirements dependent on the clinician; neither lab inclusion nor a universal no-labs pathway is established. NAD⁺ descriptions differ across surfaces, so confirm the offered route and formulation.

No numeric sermorelin or NAD⁺ price was found on the reviewed pages. The FAQ says medication is billed at shipment, but recurring-plan terms allow billing at the enrollment frequency, which may differ from shipping. The terms require cancellation before processing and make processed orders nonrefundable; the returns page refers to cancellation before shipping and final sales after carrier handoff. Treat processing as the earlier practical cutoff and request written confirmation. Obtain full debit, supply, renewal, lab and visit costs rather than assuming a calendar-month plan.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The reviewed wellness pages describe compounded treatments; confirm the exact formulation and route. The partner list does not identify your dispensing pharmacy; compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are — an identifiable facility is one whose licensure and inspection history you can look into. On the evidence, the two wellness products need separating. Sermorelin acts on the growth-hormone axis; the mechanism is real and well described, the long-term human outcome data stays thin, and no controlled trial shows it delivers the body-composition or anti-aging results it is marketed for — an oral tablet form has even less behind it than the injection. Injected or intranasal NAD⁺ has no controlled human outcome trials at all — the studied forms are the oral precursors NR and NMN, and what they demonstrate is a raised blood NAD⁺ level rather than a clinical benefit. Individual results vary.